Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients.

Department of Neuroscience, Erasmus MC, The Netherlands.
Amino Acids (Impact Factor: 3.65). 02/2007; 32(1):121-6. DOI: 10.1007/s00726-006-0284-3
Source: PubMed

ABSTRACT The aim of this study was to evaluate the effect of pegylated interferon-alpha (PEG-IFN-alpha) on the plasma citrulline/arginine ratio, regarded as an index of nitric oxide (NO) synthesis, in patients with high-risk melanoma. Forty patients were randomly assigned to either PEG-IFN-alpha treatment (n = 22) or to observation only (control group, n = 18). The treatment group received 6 microg PEG-IFN-alpha/kg once a week during 8 weeks, followed by a maintenance dose of 3 microg/kg/wk. Blood was collected at different time points, plasma concentrations of citrulline and arginine were measured and the ratio of citrulline/arginine was calculated. Patients treated with PEG-IFN-alpha showed a significant decrease in the concentrations of citrulline and in the citrulline/arginine ratio during the whole study period, both compared to baseline values and to the control group. The data suggest that therapy with PEG-IFN-alpha results in a marked decrease in the synthesis of NO in melanoma patients.


Available from: Alexander Maximiliaan Eggermont, Feb 11, 2015